WO2015003623A1 - Composition de traitement de l'arthrose - Google Patents

Composition de traitement de l'arthrose Download PDF

Info

Publication number
WO2015003623A1
WO2015003623A1 PCT/CN2014/081849 CN2014081849W WO2015003623A1 WO 2015003623 A1 WO2015003623 A1 WO 2015003623A1 CN 2014081849 W CN2014081849 W CN 2014081849W WO 2015003623 A1 WO2015003623 A1 WO 2015003623A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
combination
concentration
osteoarthritis
fat
Prior art date
Application number
PCT/CN2014/081849
Other languages
English (en)
Chinese (zh)
Inventor
曹卫
张丽
李苏克
戴成祥
汪文
Original Assignee
西比曼生物科技（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西比曼生物科技（上海）有限公司 filed Critical 西比曼生物科技（上海）有限公司
Publication of WO2015003623A1 publication Critical patent/WO2015003623A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Definitions

  • Composition for treating osteoarthritis Composition for treating osteoarthritis
  • the present invention relates to the field of medical and biomedical engineering, and in particular to a biological product for treating osteoarthritis and a preparation method thereof. Background technique
  • Osteoarthritis is a chronic joint disease characterized by degeneration, destruction and bone hyperplasia of articular cartilage. It has a high incidence and is very common in the elderly. The prevalence rate can reach 50% in people over 60 years old. 80% of people over the age of 75. Joint pain in patients with osteoarthritis often makes the patient intolerable, and the patient has a high rate of disability after onset.
  • the existing drugs for treating osteoarthritis can delay the course of disease, improve the symptoms of patients, relieve the pain of patients, but can not reverse the pathological process, can not cure osteoarthritis, and most of the side effects of drugs are obvious.
  • Surgical treatment is mainly through arthroscopy (special surgery), open surgery or artificial joint replacement. Although it can temporarily relieve pain, the long-term effect (> 10 years) is not ideal.
  • Cell therapy such as stem cells is currently the most promising new approach to the treatment of osteoarthritis.
  • Osteoarthritis often occurs in cartilage defects, but cartilage has limited ability to repair itself. Cartilage repair can often be used as the most important evaluation index for osteoarthritis treatment.
  • stem cell transplantation has been reported in a large number of studies on osteoarthritis. After stem cells are injected into the joints of osteoarthritis, they can exert immunoregulatory effects, regulate inflammation and reduce pain; secrete anti-apoptotic factors and anti-fibrotic factors to inhibit disease progression; secrete TGF- ⁇ , ⁇ -4 and other factors to promote endogenous Sexual stem cell cartilage repair; can also differentiate into chondrocytes to help repair cartilage.
  • stem cell therapy for osteoarthritis mostly uses bone marrow-derived mesenchymal stem cells.
  • the treatment of osteoarthritis with fat pluripotent cells has also been reported in many literatures. Preclinical studies and clinical studies have shown mesenchymal stem cells and fat pluripotent stem cells. It is possible to improve the condition and report an increase in cartilage content, but there is still a certain distance from the full recovery of the joint. Bone marrow mesenchymal stem cells need to be worn through the bone marrow, causing greater damage to the donor.
  • obtaining pluripotent cells from fat is more advantageous, 1) taking less damage to the human body; 2) forming CFU-F in fat
  • the pluripotent cell content of the ability is higher than 1%, and the bone marrow is less than 0.001%; 3) the fat source is rich, and the pluripotent cells are abundant; 4) the adipose-derived cells have stronger proliferative ability than the bone marrow mesenchymal stem cells. Therefore, fat pluripotent stem cells have an advantage in the treatment of osteoarthritis.
  • the stromal vascular component contains fat pluripotent cells and contains many other types of cells. It was first obtained from adipose tissue by enzymatic digestion, and can be extracted and purified to separate fatty pluripotent stem cells.
  • the stromal vascular component also has a therapeutic effect on the treatment of osteoarthritis, and the stromal vascular component can be reduced from transplantation to transplantation for 2-3 hours, which can reduce the transplantation time, and is cheap, and can also reduce the risk in cell culture, but the fat contained therein can be The amount of cells is small.
  • stromal vascular components contain pluripotent cells of CD34+CD31- and CD34+CD31+, It has a strong ability to promote angiogenesis, and the expression of CD34+ in the pluripotent cells after culture is reduced or disappeared.
  • stromal vascular components or purified pluripotent cells of CD34+CD31- and CD34+CD31+ have been used in combination with fat pluripotent cells for the treatment of osteoarthritis, and the combination of the two may improve angiogenesis. Produce significant improvements in governance.
  • Platelet-rich plasma secretes a variety of cytokines that promote cartilage recovery, but the role of PRP in the treatment of osteoarthritis is controversial, and studies have reported negative effects on cartilage repair.
  • the injection volume of the existing intra-articular injection products is generally too large, such as injecting 5 ml, 8.5 ml of the liquid composition into the joint, and excessive fluid injection into the joint cavity causes an increase in pressure and causes discomfort to the patient.
  • An object of the present invention is to provide a liquid composition for the treatment of osteoarthritis which is optimized in composition, has a low content of impurities, and has a high content of active ingredients.
  • a composition for treating osteoarthritis comprising the following components:
  • a fat-containing pluripotent cell component comprising (al) a stromal vascular component; and/or (a2) a purified or cultured expanded pluripotent cell;
  • the composition is a liquid composition.
  • the stromal vascular component comprises a fat pluripotent cell.
  • the fatty pluripotent cells in (a2) are selected from the group consisting of: a fatty pluripotent cell purified from a stromal vascular component, a culture-expanded fat pluripotent cell, or a combination thereof.
  • the culture-amplified adipose pluripotent cells are expanded in serum-free medium or serum-containing medium.
  • the fatty pluripotent cellular component is reconstituted immediately or cryopreserved.
  • the fat-containing pluripotent cell component comprises cells selected from the group consisting of: adipocytes, endothelial cells, smooth muscle cells, pericytes, fibroblasts, mast cells, nerve cells, fat precursors cell, Lymphocytes, blood cells, stromal cells, macrophages, or a combination thereof.
  • the fat pluripotent cell content is 10 to 100% of the total cell amount.
  • the fatty pluripotent cellular component is autologous or allogeneic.
  • the fatty pluripotent cellular component has a cartilage differentiation potential.
  • the platelet-rich plasma is selected from the group consisting of activated PRP, unactivated PRP liquid, PRP gel, or a combination thereof.
  • the stromal vascular component comprises a cell selected from the group consisting of:
  • CD45-CD235a-CD31-CD34+ cells, and/or CD34+CD31+ cells are CD45-CD235a-CD31-CD34+ cells, and/or CD34+CD31+ cells.
  • the fat-containing pluripotent cell component is a CD45-CD235a-CD31-CD34+ cell, and/or a CD45-CD13+CD36+CD73+ cell-enriched fat-containing pluripotent cell component.
  • CD45-CD 13+CD36+CD73+ cell enrichment means that the content of CD45-CD235a-CD31-CD34+ cells and/or CD45-CD 13+CD36+CD73+ cells is 15-100% of the total cells in the fraction.
  • the concentration of red blood cells in the platelet rich plasma is 5 X 10 5 /mL. In another preferred embodiment, the concentration of leukocytes in the platelet-rich plasma is 4 X 10 5 /mL. In another preferred embodiment, the concentration of red blood cells in the platelet rich plasma is 4 X 10 5 /mL. In another preferred embodiment, the platelet-rich plasma has a platelet concentration ranging from 0.5 X 10 6 to 1.5 X 10 1 Q /mL, and the total concentration of leukocytes and red blood cells in the plasma is 10 X 10 5 /mL. ; and / or
  • the concentration of the fatty pluripotent cells in the composition is from 10 5 to 10 8 /mL.
  • the platelet-rich plasma has a platelet concentration ranging from 5 X 10 7 to 5 X 10 8 /mL.
  • the fat pluripotent cells are present in the composition at a concentration of 1 X 10 6 -5 X 10 7 /mL.
  • the plasma further comprises a growth factor selected from the group consisting of TGF- ⁇ PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or
  • the cytokine is further included in the composition of the fat-containing pluripotent cell, and the cytokine is selected from the group consisting of TGF- ⁇ , TIMPs, VEGF, HGF, PGE2, IGF-1, MIP. -la, IL-6, IDO, GM-CSF, IL-1RA, IL-12p40, IL-10, IL-13, or a combination thereof;
  • the surface marker of the expression of the fatty pluripotent cell is selected from the group consisting of CD90, CD34, CD10, CD36, CDCD45, CD 105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD 13, CD63, CD166, CD31, CD106, CD71, or a combination thereof; and/or
  • the surface marker not expressed by the fatty pluripotent cell is selected from the group consisting of CD133, CD146, CD14, CD117, CD1 lb, CD79a, CD19, HLA-DR, or a combination thereof.
  • the polysaccharide is selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, dextran, alginic acid, chitin, or a combination thereof; and/or
  • the pharmaceutically acceptable buffer is selected from the group consisting of sodium chloride buffer, calcium chloride buffer, calcium magnesium phosphate buffer, calcium magnesium sulfate buffer, calcium magnesium carboxylate buffer, glucose. Phosphate buffer, 4-hydroxyethylpiperazine ethanesulfonic acid buffer, serum-containing medium, serum-free medium, or a combination thereof.
  • the polysaccharide has a mass percentage concentration of 0.001 to 30% based on the total mass of the solution.
  • the pH of the buffer is 6.7-7.5.
  • the composition is a unit dosage form, and the unit dosage form has a volume of 4 mL, preferably 3 mL.
  • the composition has a single use volume of 0.15-3 mL.
  • the ratio of the fat pluripotent cell concentration to the platelet concentration is 100: 1-1: 100000.
  • the ratio of the pluripotent cell concentration to the platelet concentration is 10: 1-1: 1000.
  • the ratio of the pluripotent cell concentration to the platelet concentration is 1: 5-1: 50.
  • a process for the preparation of a composition according to the first aspect of the invention comprising the steps of: mixing components a, b, c and d to form a composition.
  • the method includes:
  • step a includes:
  • the stromal vascular component is derived from peripheral blood.
  • the stromal vascular component is obtained using an enzymatic digestion method or an ultrasonic cavitation method.
  • the step of isolating and purifying the pluripotent cells in the vascular matrix component comprises: separating CD45-CD235a-CD31-CD34+ cells and/or CD34+CD31+ cells by flow cytometry.
  • the step of isolating the platelet rich plasma comprises: separating the plasma with a fully automated and semi-automated device.
  • the platelet-rich plasma removes red blood cells and white blood cells by centrifugation or filtration.
  • a preparation for the treatment of osteoarthritis which comprises the composition according to the first aspect of the invention as an active ingredient.
  • the preparation is an injection.
  • the formulation is for injecting a diseased joint of a patient.
  • the concentration of the fatty pluripotent cells is 10 5 -10 8 /mL;
  • the concentration of platelets is 5 X 10 7 -5 X 10 8 /mL;
  • the concentration of white blood cells is 5 X 10 5 mL;
  • the concentration of red blood cells is 5 X 10 5 mL;
  • the volume of the preparation is 4 mL
  • the plasma further comprises a growth factor selected from the group consisting of TGF-i3, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or a combination thereof;
  • a growth factor selected from the group consisting of TGF-i3, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or a combination thereof;
  • the fat-containing pluripotent cell component further comprises a cytokine, and the cytokine is selected from the group consisting of:
  • TGF- ⁇ TIMPs, VEGF, HGF, PGE2, IGF-1, MIP-la, IL-6, IDO, GM-CSF, IL-1RA, IL-12p40, IL-10, IL-13, or a combination thereof;
  • the surface marker for expression of the fat-containing pluripotent cell component is selected from the group consisting of CD90, CD34, CD10, CD36, CDCD45, CD105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD 13, CD63, CD166, CD31, CD106, CD71, or a combination thereof;
  • the surface marker not expressed by the fat-containing pluripotent cellular component is selected from the group consisting of CD133, CD146, CD14, CD117, CD1 lb, CD79 a, CD19, HLA-DR, or a combination thereof.
  • the formulation has a volume of 3 mL.
  • the formulation has a volume of from 0.15 to 3 mL.
  • a reagent combination or kit comprising: a. a fat-containing pluripotent cell component, wherein said component comprises (al) a stromal vascular component,
  • the stromal vascular component comprises fat pluripotent cells; and/or (a2) purified or cultured expanded pluripotent cells;
  • the method of use comprises: mixing components a, b, c and d for treating patients with osteoarthritis.
  • the stromal vascular component comprises a fat pluripotent cell.
  • the fatty pluripotent cells in (a2) are selected from the group consisting of: a fatty pluripotent cell purified from a stromal vascular component, a culture-expanded fat pluripotent cell, or a combination thereof.
  • the treatment comprises promoting regeneration of cartilage in the patient with osteoarthritis.
  • a method of treating osteoarthritis comprising: administering to a patient an effective amount of the composition of the first aspect of the invention, or administering an effective amount of the patient to the patient The preparation of the second aspect of the invention.
  • the treatment comprises promoting regeneration of cartilage in the patient with osteoarthritis.
  • FIG. 1 is a control diagram for treating the condition of repairing articular cartilage in Example 2 of the present invention.
  • Fig. 2 is a comparison diagram of Mankin scores of each group in Example 2 of the present invention.
  • Fig. 3 is a graph showing the detection of TNF-ci content in the joint fluid after treatment in Example 2 of the present invention.
  • Fig. 4 is a graph showing the total amount of articular cartilage after treatment for 10 weeks in Example 2 of the present invention.
  • Fig. 5 is a graph showing the pain relief score of knee osteoarthritis in Example 3 of the present invention.
  • Fig. 6 is a graph showing the symptom relief score of knee osteoarthritis in Example 3 of the present invention.
  • Fig. 7 is a graph showing the knee joint function (W0MAC) score in the third embodiment of the present invention.
  • Fig. 8 is a view showing the volume of the knee joint cartilage in Example 3 of the present invention.
  • Fig. 9 is a comparison diagram of evaluation results of treatment results of a subject to be treated in Example 4 of the present invention. detailed description
  • the present inventors After long-term and intensive research, the present inventors have unexpectedly discovered that a platelet-rich plasma-binding pluripotent cell which separates and purifies and removes white blood cells and red blood cells is used to prepare a biological composition for treating osteoarthritis patients. Unexpected therapeutic effects. And when the biological product is made or used as a joint injection, it is only necessary to inject a small amount of liquid to achieve a very good therapeutic effect. Based on the above findings, the inventors completed the present invention. Osteoarthritis
  • Osteoarthritis is a chronic joint disease. Its main changes are the degeneration of the articular cartilage surface and secondary bone hyperplasia, which is manifested in joint pain and inflexibility. X-ray shows narrowing of joint space, subchondral Dense bone, trabecular bone fracture, hardening and cystic changes; lip-like hyperplasia at the edge of the joint; The joint surface is uneven; the cartilage in the joint is spalled, the bone is broken into the joint, and the joint is free.
  • the osteoarthritis may be osteoarthritis selected from the group consisting of knee osteoarthritis, spinal osteoarthritis, hip osteoarthritis, or a combination thereof.
  • the osteoarthritis of the present invention is preferably knee osteoarthritis. fat
  • Adipose tissue materials can be derived from the waist, hips, abdomen, thighs, upper arms and more. Those skilled in the art can obtain adipose tissue using a general technical method including, but not limited to, aspiration, surgical separation, and the like.
  • the adipose tissue or the fat raw material is not particularly limited, and may be an adipose tissue derived from any part of an animal or a human, preferably a human adipose tissue.
  • the adipose tissue may be a tissue of a part of the waist, the buttocks, the abdomen, the thigh, the upper arm, and the like.
  • Matrix vascular component may be a tissue of a part of the waist, the buttocks, the abdomen, the thigh, the upper arm, and the like.
  • the stromal vascular component contains fat pluripotent cells and contains many other types of cells. It was first obtained from adipose tissue by enzymatic digestion, and can be extracted and purified to separate fatty pluripotent stem cells. The stromal vascular component also has a therapeutic effect on the treatment of osteoarthritis, and the stromal vascular component is isolated from transplantation to 2-3 hours, which can reduce the transplantation time, is inexpensive, and can reduce the risk in cell culture. At the same time, pluripotent cells containing CD34+CD31- and CD34+CD31+ in the vascular component of the stromal have strong ability to promote angiogenesis, and have obvious effects on the body. Fat-rich pluripotent cell component
  • Fat pluripotent cells have been reported for the treatment of osteoarthritis.
  • the pluripotent cells obtained from fat are simpler, more widely available, and have a higher pluripotent cell content with CFU-F formation ability in fat. Strong.
  • the stromal vascular component has a therapeutic effect on osteoarthritis, and the stromal vascular component is isolated from transplantation to 2-3 hours, which can reduce the transplantation time, and is inexpensive, and can also reduce the risk in cell culture, and the stromal vascular component contains CD34+.
  • the pluripotent cells of CD31- and CD34+CD31+ have strong ability to promote angiogenesis.
  • the vascular vascular component contains insufficient concentration of fat pluripotent cells, which affects the therapeutic effect.
  • the expression of CD34+ in the pluripotent cells after culture is reduced or disappeared, which also leads to poor therapeutic effect.
  • the stromal vascular component is used in combination with purified or cultured expanded pluripotent cells, thereby improving the respective defects of the above two, improving the angiogenic ability, and improving the effect more conspicuously.
  • the surface marker of the expression of the fatty pluripotent cell is selected from the group consisting of CD90, CD34, CD10, CD36, CDCD45, CD105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD 13 , CD 63 , CD 166 , CD 31 , CD 106 , CD 71 , or a combination thereof; and/or
  • the surface marker not expressed by the fatty pluripotent cell is selected from the group consisting of CD133, CD146, CD14, CD117, CD1 lb, CD79a, CD19, HLA-DR, or a combination thereof.
  • Platelet-rich blood paddle (PRP) is selected from the group consisting of CD133, CD146, CD14, CD117, CD1 lb, CD79a, CD19, HLA-DR, or a combination thereof.
  • platelet-rich plasma preparation is highly variable, with mononuclear cells ranging from 107ML to 10 lfl / ML, and there is currently no reported study on its optimal range of content.
  • the present invention employs platelet-rich plasma which separates and removes white blood cells and red blood cells, and unexpectedly obtains a better therapeutic effect.
  • the concentration of platelets is 5 X 10 7 -5 X 10 8 /mL
  • the leukocyte concentration is 5 X 10 5 mL
  • the concentration of red blood cells is 5 X 10 5 mL.
  • the plasma further comprises a growth factor selected from the group consisting of TGF- ⁇ PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or combination.
  • a growth factor selected from the group consisting of TGF- ⁇ PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or combination.
  • the present invention provides a composition for treating osteoarthritis, the composition comprising the following components: a. a fat-containing pluripotent cell component; the component comprising (al) a stromal vascular component, The stromal vascular component contains pluripotent cells; and (a2) purified or cultured expanded pluripotent cells;
  • fatty pluripotent cells are selected from the group consisting of: fat pluripotent cells purified from stromal vascular components, cultured expanded pluripotent cells, or a combination thereof; b. platelet-rich plasma;
  • the composition is preferably a liquid composition.
  • the polysaccharide component has buffering stress, shielding effect, anti-inflammatory, pain relief and protection of cartilage.
  • the addition of a buffer last stabilizes the solution ra, and a component that promotes platelet-rich plasma release factor can be added.
  • the polysaccharide includes (but is not limited to, hyaluronic acid, hyaluronic acid derivative, dextran, alginic acid, chitin, or a combination thereof.
  • the polysaccharide has a mass percentage concentration of 0.001 to 30%.
  • the buffer is used to adjust the pH of the composition to reduce the pain of the patient during injection.
  • the pharmaceutically acceptable buffers described in the present invention include, but are not limited to:: sodium chloride buffer, calcium chloride buffer, calcium magnesium phosphate buffer, calcium magnesium sulfate buffer, calcium Magnesium carboxylate buffer, glucose phosphate buffer, 4-hydroxyethylpiperazine ethanesulfonic acid buffer, serum-containing medium, serum-free medium, or a combination thereof.
  • the buffer is a calcium salt.
  • the pH of the buffer is 6.7-7.5.
  • Commercially available products for the treatment of osteoarthritis generally have a problem of large intra-injection volume, such as a total volume of 5 ml ⁇ 8.
  • the total injection volume can be reduced to 4 mL, which is advantageous for increasing the concentration of pluripotent cells and platelet-rich plasma release factors, and also promoting cell migration. Repair to the affected area.
  • the composition is a unit dosage form, and the unit dosage form has a volume of 4 mL, preferably 3 mL.
  • the unit dosage form has a volume of from 0.15 to 3 mL.
  • the ratio of the fat pluripotent cell concentration to the platelet concentration is 100: 1-1: 100000;
  • the ratio of the pluripotent cell concentration to the platelet concentration is 10: 1-1: 1000;
  • the ratio of the pluripotent cell concentration to the platelet concentration is 1:5-1:50.
  • the composition can be used directly for injection into a joint site of an osteoarthritic patient, or for the preparation of a preparation for treating osteoarthritis.
  • the preparation may be in any dosage form, preferably an injection.
  • the concentration of the fatty pluripotent cells is 10 5 -10 8 /mL;
  • the concentration of platelets is 5 X 10 7 -5 X 10 8 /mL;
  • the total concentration of white blood cells and red blood cells is 5 X 10 5 mL;
  • the plasma further comprises a growth factor selected from the group consisting of TGF-e, PDGF, VEGF, IL-1, IL-6,
  • TNF TNF, IRAP, CTGF, EGF, IGF, BFGF, or a combination thereof;
  • the fat-containing pluripotent cell component further comprises a cytokine, and the cytokine is selected from the group consisting of TGF- ⁇ , TIMPs, VEGF, HGF, PGE2, IGF-1, MIP-la, IL-6 , IDO, GM-CSF, IL-1RA, IL-12p40, IL-10, IL-13, or a combination thereof;
  • the surface marker of the expression of the fatty pluripotent cell is selected from the group consisting of CD90, CD34, CD10, CD36,
  • CDCD45 CD 105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD 13, CD63, CD 166, CD31, CD 106, CD71, or a combination thereof;
  • the surface marker not expressed by the fatty pluripotent cell is selected from the group consisting of CD133, CD146, CD14, CD117, CD1 lb, CD79 a, CD19, HLA-DR, or a combination thereof.
  • the preparation is administered in a single dose of 3 mL.
  • the main advantages of the invention include:
  • the present invention employs PRP from which white blood cells and red blood cells are removed, so that the composition provided by the present invention has a better therapeutic effect.
  • PRP white blood cells and red blood cells are removed.
  • a stromal vascular component in combination with a cultured pluripotent pluripotent cell, and using a lipid-containing pluripotent cellular component purified by CD34+CD31- and CD34+CD31+ pluripotent cells, the blood vessel of the composition of the present invention The regenerative capacity is stronger than the prior art, and the treatment effect is better.
  • adipose tissue was taken from the patient's fat supply section, and the adipose tissue was centrifuged at 800 g X for 5 minutes. The supernatant was centrifuged for 45 minutes with PBS containing 0.075% collagenase, centrifuged, the supernatant was discarded, and the lower layer was resuspended in DMEM. Cell pellets. Collagenase was removed by washing 3 times. At the same time, 500 ml of aspirating fluid was collected, centrifuged at 800 g X for 5 minutes, the supernatant was discarded, and the mixture was whipped for 30 seconds by adding 200 ml of physiological saline. The addition of 22.
  • the isolated vascular matrix component cells were resuspended in FACS buffer (PBS containing 1% BSA and 0.05% sodium azide), the cells were adjusted to 10 5 cells, the antibody was added, mixed, and incubated on ice.
  • FACSvantageTM Becton Di ckinson sorting based on expression of cell surface marker levels
  • CD45-CD235a-CD31-CD34+ cells and CD34+CD31+ cells The concentration of the cells was adjusted to 3 X 10 ⁇ /ML by adding DMEM.
  • the obtained stromal vascular fraction cells were centrifuged, resuspended in serum-free medium, and the cell concentration was adjusted to
  • the mixed pluripotent cell sample was taken, and 5 ⁇ 10 6 cells were placed in a 1.5 ml centrifuge tube and centrifuged at 3000 r/min for 5 minutes, and the supernatant was discarded.
  • Add 350 ⁇ l of FACS buffer mix gently, centrifuge at 3000 r/min for 5 minutes, discard the supernatant, and repeat the wash twice.
  • 100 ⁇ l of 1 instrument buffer was added to the obtained cell pellet, and the suspension cells were gently mixed, and the cell suspension was transferred to a FACS-dedicated tube, and instrument detection and analysis were performed on a BD flow cytometer.
  • the surface markers detected by the mixed pluripotent cells were: CD90, CD34, CD10, CD36, CD45, CD73, CD13, CD31, CD106, CD71, and the surface markers not expressed were: CD133, CD14, CD79, CD19, HLA - DR.
  • the mixed pluripotent cell samples were inoculated into 24-well plates, fused to 80%, and replaced with cartilage-inducing solution (10 ng/mL TGF, 10 mmol/mL dexamethasone, 50 mg/mL vitamin C, high glucose DMEM). Cheng), change the liquid once every 3 days, induce 1 1 day, the control group is used.
  • the coverslips were pre-placed in the culture wells, and the cells were covered with coverslips.
  • the cells were removed from the slides at 11 days, and the volume fraction was fixed in 10% formaldehyde for 1 hour, washed in PBS for 15 minutes, rinsed once with distilled water, and added dropwise.
  • g/L a new blue staining, dyeing for 3 hours, adding 95% ethanol, washing off the excess dye solution, drying, neutral gum seal.
  • the pluripotent cells were able to differentiate into chondrocytes, and the results of the differentiation experiment in the control group were negative.
  • the patient's 20ML peripheral blood was drawn, shaken, placed in a centrifuge tube, and centrifuged twice.
  • the first centrifugation speed was 1500 rpm, which was 10 minutes.
  • After centrifugation it is divided into upper layer plasma and lower layer red blood cells. Discard the red blood cells located in the lower part of the centrifuge tube and pipet all the plasma to another centrifuge tube.
  • the leukocytes were removed by filtering the plasma using a leukocyte filter.
  • the filtered plasma was subjected to a second centrifugation at a speed of 3000 rpm and centrifuged for 10 minutes.
  • the plasma was divided into upper platelet-poor plasma and lower platelet-rich plasma, and the platelet-rich plasma was taken.
  • a pocH-lOOi blood cell analyzer (Sysmex, Japan) to detect the platelet content of the isolated platelet-rich 9. 7 X 10 7 / ML, white blood cell content 1. IX 10 5 / ML, red blood cell content 4. 3 X 10 5 /ML.
  • ELISA for detection of cytokine expression in pluripotent cell culture supernatants and platelet-rich plasma
  • the mixed pluripotent cell samples were inoculated into the culture dish at 105 cells/cm 2 , and the culture supernatant was taken after adherent culture for 36 hours, and the expression of TGF- ⁇ , HGF, IGF-1, and VEGF was detected by ELISA.
  • Platelet-rich plasma was added to the activator at a volume ratio of 1:9 (500 U thrombin lyophilized powder dissolved in 1 mL of 10% calcium chloride) to activate platelet-rich plasma, allowed to stand at room temperature for 24 hours, 4 000 rpm The extract was extracted by centrifugation for 15 minutes, and the expression of cytokines was measured by ELISA.
  • the pluripotent stem cell component of the biological product was added with 10% DMS0, cooled in a program desuperheater, stored in liquid nitrogen at -196 °C, and rapidly resuscitated in a 37 °C water bath during use, and the cell viability after resuscitation was >90%.
  • Platelet-rich plasma was added to 5% DMS0 and stored in a -80 °C freezer, and rewarmed at room temperature.
  • Hyaluronic acid and 10% calcium chloride buffer are stored at 4 ° C and rewarmed at room temperature.
  • CD45-CD235a-CD31-CD34+ and CD45-CD13+CD36+CD73+ pluripotent cell content The final concentration of pluripotent cells is 6. 5 X 10 6 / ML.
  • the platelet content of the isolated platelet-rich plasma was measured by a pocH-100i blood cell analyzer (Sysmex, Japan) at a rate of 5 X 10 7 /ML, a white blood cell content of 5 X 10 4 /ML, and a red blood cell content of 1. 2 X 10 5 / ML.
  • the syringe was used to inject 0.3 ml of biological products into the joints with osteoarthritis under ultrasound guidance, and the bolus was slowly injected.
  • Fig. 1 The normal knee joint cartilage surface is intact and the chondrocytes are normal.
  • the untreated knee joint cartilage surface is obviously damaged, the exfoliation phenomenon is obvious, the superficial cartilage vacuolar degeneration, the mature chondrocyte column line disappears, and the structure is destroyed.
  • the damaged cartilage surface recovered intact, the cartilage did not undergo vacuolar degeneration, and the mature chondrocyte column line recovered.
  • CD45-CD13+CD36+CD73+ pluripotent cell content The final concentration of pluripotent cells was 4.97 X 10 7 cells/ML.
  • the platelet content in the isolated platelet-rich plasma was measured to be 5 X 10 8 /ML, the white blood cell content was 9 X 10 4 /ML, and the red blood cell content was 4 ⁇ 10 5 /ML.
  • Group 1 patients with knee osteoarthritis were divided into two groups.
  • Group 1 patients underwent ultrasound-guided slow injection of 3 ml of biological products into the joint cavity of osteoarthritis;
  • Group 2 patients received injected biologics with hyaluronic acid to increase the volume to 8 ML, under ultrasound-guided slow injection into osteoarthritis joint.
  • Follow-up was performed at 2, 5, 10, 18, and 52 weeks after surgery.
  • the biologic product was injected into the joint cavity of osteoarthritis, and the 3 ml volume of the biological product showed a feeling of soreness and pain of less than 8 ml of the biological product during the injection.
  • the pain relief score is shown in Figure 5, and the symptom relief score is shown in Figure 6.
  • the results showed that a 3 ml biologic product was superior to 8 ml of biologics in terms of pain and symptom relief.
  • the knee function (W0MAC) score is shown in Figure 7.
  • the results show that a 3 ml volume of biological products can effectively improve knee function.
  • Platelet-rich plasma is used for osteoarthritis treatment after removing leukocytes and red blood cells — platelet-rich plasma separation and reduction of white blood cell and red blood cell content
  • the dog femoral artery blood was extracted 12 mL, the first centrifugation speed was 1500 r/min, and the cells were centrifuged for 10 minutes, and the upper layer of plasma was aspirated to another centrifuge tube.
  • the plasma was removed using a leukocyte filter to remove white blood cells.
  • the platelet-rich plasma was centrifuged at a rate of 3000 r/min and centrifuged for 10 minutes to remove the upper white blood cells and red blood cell liquid.
  • the platelet-rich plasma was taken, resuspended in physiological saline, and centrifuged three times.
  • the pecH-100i blood cell analyzer (Sysmex, Japan) was used to detect the platelet content of the isolated platelet-rich plasma by 3 X 10 8 /ML, the white blood cell content of 3 X 10 3 /ML, and the red blood cell content of 7 X 10 4 /ML.
  • the platelet content of the platelet-rich plasma without red blood cell and white blood cell removal was 2. 8 X 10 8 /ML, the white blood cell content was IX 10 6 /ML, and the red blood cell content was 5 X 10 6 /ML.
  • the posterior cruciate ligamentectomy and the medial meniscus resection were performed in the posterior left knee joint of the dog.
  • Model dogs with osteoarthritis were divided into two groups of 10 animals each.
  • the sputum of the group 1 was slowly injected with 0.5 ml of platelet-rich plasma to remove the red blood cells and white blood cells to the osteoarthritis joint;
  • the dog of group 2 was slowly injected under ultrasound guidance 0. 5 ml of the red blood cells and white blood cells were not removed.
  • Platelet plasma to osteoarthritic joints were followed up at 30, 60 and 90 days postoperatively.
  • the dog's treatment, mobility limitation, and dysfunction were evaluated.
  • the results showed that the overall condition of the treatment group was significantly improved compared with the control group (total score).
  • the condition of the limp was improved obviously, and the walking was significantly improved after 30 days (P ⁇ 0.05), and further improved to 60 days after 60 days; the improvement of the leap in the jump was more obvious, about 30 days.
  • the improvement in joint mobility was also quite noticeable, with a significant improvement in about 30 days (P ⁇ 0.01), and it was not repeated until the end of the experiment.
  • the overall scores of the treatment group and the control group were compared, and the results are shown in Fig. 9.
  • the biologic product composition provided by the invention has obvious recovery of cartilage in the treatment of osteoarthritis and animal experimental treatment, and has significant difference compared with the control group, and the recovery condition is similar to that of the normal group.
  • the neovascularization of the treatment group was better than that of the control group; the inflammatory factor of the joint fluid was significantly down-regulated after treatment, and there was no significant difference from the normal value.
  • Clinical patients received treatment, pain and discomfort were weak, knee function recovered well, and the score was significantly higher than the control group.
  • the results show that the composition provided by the present invention can promote the regeneration of cartilage in patients with osteoarthritis and is very effective in treating osteoarthritis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition destinée au traitement de l'arthrose. L'invention concerne de manière spécifique un produit biologique destiné au traitement de l'arthrose, sa méthode de préparation, une préparation faite à l'aide du produit, une combinaison de réactif, et un kit. Le produit est fait à l'aide de plasma qui ne contient pas de globule rouge ou de globule blanc et est riche en plaquettes sanguines et en un composé cellulaire contenant de la graisse multifonctionnel en association avec d'autres composés.
PCT/CN2014/081849 2013-07-10 2014-07-08 Composition de traitement de l'arthrose WO2015003623A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310289978.X 2013-07-10
CN201310289978.XA CN103340904B (zh) 2013-07-10 2013-07-10 治疗骨关节炎的组合物

Publications (1)

Publication Number Publication Date
WO2015003623A1 true WO2015003623A1 (fr) 2015-01-15

Family

ID=49275764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/081849 WO2015003623A1 (fr) 2013-07-10 2014-07-08 Composition de traitement de l'arthrose

Country Status (2)

Country Link
CN (1) CN103340904B (fr)
WO (1) WO2015003623A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103340904B (zh) * 2013-07-10 2016-03-23 西比曼生物科技（香港）有限公司 治疗骨关节炎的组合物
WO2015085957A1 (fr) * 2013-12-13 2015-06-18 星耀控股有限公司 Composition pour le traitement de l'arthrose
CN104706675A (zh) * 2013-12-13 2015-06-17 星耀控股有限公司 治疗骨关节炎的组合物
CN104707141A (zh) * 2013-12-13 2015-06-17 星耀控股有限公司 治疗骨关节炎的组合物
CN104127884A (zh) * 2014-07-14 2014-11-05 云南省第一人民医院 一种治疗类风湿性关节炎的微囊及其制备方法
CN104546915B (zh) * 2015-02-16 2018-12-11 天晴干细胞股份有限公司 一种治疗骨性关节炎的组合物的制备方法
CN104739862A (zh) * 2015-04-03 2015-07-01 广州赛莱拉干细胞科技股份有限公司 一种组合物及其应用
CN106390099A (zh) * 2016-11-07 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种牙髓干细胞组合物及其应用
CN106540334A (zh) * 2016-12-06 2017-03-29 广州赛莱拉干细胞科技股份有限公司 一种组合物及其应用
DE102018102807A1 (de) * 2018-02-08 2019-08-08 Stefan Eggli Mittel zum Clustern von Rezeptoren
CN108653329A (zh) * 2018-05-28 2018-10-16 广东唯泰生物科技有限公司 一种用于治疗骨关节炎的药物及其制备方法
CN108795853B (zh) * 2018-05-28 2021-08-24 天津博雅秀岩生物技术有限公司 制备犬胎膜间充质干细胞的方法和犬胎膜间充质干细胞
CN114146096B (zh) * 2021-11-25 2024-04-02 成都清科生物科技有限公司 一种富含细胞因子的条件血清的制备方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102205147A (zh) * 2011-05-16 2011-10-05 中国人民解放军第四军医大学 一种脂肪颗粒组织复合svf和prf的移植材料及其制备方法和用途
CN102232970A (zh) * 2010-04-22 2011-11-09 董运海 一种治疗骨损伤细胞注射剂及其制备方法
CN102470190A (zh) * 2009-07-02 2012-05-23 菲迪亚医药公司 适用于治疗骨关节炎、韧带损伤和关节失调的生物材料
CN103340904A (zh) * 2013-07-10 2013-10-09 西比曼生物科技（上海）有限公司 治疗骨关节炎的组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102470190A (zh) * 2009-07-02 2012-05-23 菲迪亚医药公司 适用于治疗骨关节炎、韧带损伤和关节失调的生物材料
CN102232970A (zh) * 2010-04-22 2011-11-09 董运海 一种治疗骨损伤细胞注射剂及其制备方法
CN102205147A (zh) * 2011-05-16 2011-10-05 中国人民解放军第四军医大学 一种脂肪颗粒组织复合svf和prf的移植材料及其制备方法和用途
CN103340904A (zh) * 2013-07-10 2013-10-09 西比曼生物科技（上海）有限公司 治疗骨关节炎的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PHUC VAN PHAM ET AL.: "Transplantation of Nonexpanded Adipose Stromal Vascular Fraction and Platelet-Rich Plasma for Articular Cartilage Injury Treatment in Mice Model", JOURNAL OF MEDICAL ENGINEERING, vol. 2013, no. 1, 31 January 2013 (2013-01-31), pages 1 - 7 *
SANDEEP PATEL ET AL.: "Treatment With Platelet-Rich Plasma Is More Effective Than Placebo for Knee Osteoarthritis", THE AMERICAN JOURNAL OF SPORTS MEDICINE, vol. 41, no. 2, 28 February 2013 (2013-02-28), pages 358 *

Also Published As

Publication number Publication date
CN103340904B (zh) 2016-03-23
CN103340904A (zh) 2013-10-09

Similar Documents

Publication Publication Date Title
WO2015003623A1 (fr) Composition de traitement de l'arthrose
US11236324B2 (en) Isolation of stem cells from adipose tissue by ultrasonic cavitation, and methods of use
US20120201791A1 (en) Methods of treating diseases or conditions using mesenchymal stem cells
CN104707140A (zh) 治疗骨关节炎的组合物
US9650608B2 (en) Activating adipose-derived stem cells for transplantation
JP2020519645A (ja) 脂肪組織由来幹細胞による多発性硬化症の治療
CN110935010A (zh) 一种干细胞制剂和生长因子组合物及其制备方法和应用
JP2014529406A (ja) 血管周囲薬用細胞の単離および治療的使用
CN104707141A (zh) 治疗骨关节炎的组合物
WO2015085957A1 (fr) Composition pour le traitement de l'arthrose
JP7516045B2 (ja) 筋骨格疾患のための再生・細胞療法
CN104706675A (zh) 治疗骨关节炎的组合物
WO2016141883A1 (fr) Composition pour le traitement d'anomalies du cartilage articulaire
WO2014075634A1 (fr) Utilisation d'une cellule de couche stroma-vasculaire et d'une cellule progénitrice mésenchymateuse pour la prévention ou le traitement de l'arthrose
WO2014090111A1 (fr) Utilisation de cellules de fraction vasculaire stromale et de cellules progénitrices mésenchymateuses pour la prévention ou le traitement de la polyarthrite rhumatoïde
JP6250706B2 (ja) 変形性関節症の予防または治療における異系間質血管層細胞および異系間葉前駆細胞の使用
KR20140049772A (ko) 근골격계 질환의 예방 또는 치료용 조성물
CN118165927A (zh) 一种人脐带间充质干细胞制剂、制备方法及其在治疗膝骨关节炎中的应用
WO2023081057A1 (fr) Compositions de cellules régénératives d'origine utérine avec amorce et leurs utilisations
CN103961374A (zh) 异体间质血管层细胞和异体间充质祖细胞在预防或治疗类风湿性关节炎中的应用
CN110885785A (zh) 一种分离培养间充质干细胞的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14823753

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14823753

Country of ref document: EP

Kind code of ref document: A1